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Abstract
Facioscapulohumeral muscular dystrophy (FSHD) is typically an adult onset dominant
myopathy. Epigenetic changes in the chromosome 4q35 region linked to both forms of
FSHD lead to a relaxation of repression and increased somatic expression of DUX4-fl
(DUX4-full length), the pathogenic alternative splicing isoform of the DUX4 gene. DUX4-fl
encodes a transcription factor expressed in healthy testis and pluripotent stem cells; how-
ever, in FSHD, increased levels of DUX4-fl in myogenic cells lead to aberrant regulation of
target genes. DUX4-fl has proven difficult to study in vivo; thus, little is known about its nor-
mal and pathogenic roles. The endogenous expression of DUX4-fl in FSHD-derived human
muscle and myogenic cells is extremely low, exogenous expression of DUX4-fl in somatic
cells rapidly induces cytotoxicity, and, due in part to the lack of conservation beyond primate
lineages, viable animal models based on DUX4-fl have been difficult to generate. By con-
trast, the FRG1 (FSHD region gene 1), which is linked to FSHD, is evolutionarily conserved
from invertebrates to humans, and has been studied in several model organisms. FRG1
expression is critical for the development of musculature and vasculature, and overexpres-
sion of FRG1 produces a myopathic phenotype, yet the normal and pathological functions
of FRG1 are not well understood. Interestingly, DUX4 and FRG1 were recently linked when
the latter was identified as a direct transcriptional target of DUX4-FL. To better understand
the pathways affected in FSHD by DUX4-fl and FRG1, we generated transgenic lines of
Drosophila expressing either gene under control of the UAS/GAL4 binary system. Utilizing
these lines, we generated screenable phenotypes recapitulating certain known conse-
quences of DUX4-fl or FRG1 overexpression. These transgenic Drosophila lines provide
resources to dissect the pathways affected by DUX4-fl or FRG1 in a genetically tractable
organism and may provide insight into both muscle development and pathogenic mecha-
nisms in FSHD.
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD), one of the most prevalent late onset myop-
athies [~5–12 clinically affected subjects per 100,000 [1, 2]], is characterized by progressive,
often asymmetric, weakness and atrophy of specific muscle groups [3–5]. The onset of clinical
presentation normally occurs in the second or third decade of life with the muscles of the face
and upper body typically affected first, followed by muscles of the lower extremities [3, 4]; how-
ever, there is a great range in clinical severity between FSHD subjects. For example, in the
severe infantile cases, clinical weakness is apparent from early childhood [6–8], while other car-
riers may remain asymptomatic throughout their lifetimes [3, 9–15]. Overall, individual FSHD
patients exhibit wide variability in age of onset, disease progression, and clinical severity, sug-
gestive of genetic or epigenetic modifiers of the pathogenic pathway [3, 4, 7, 9, 10, 14–17].
There are two genetic classes of FSHD (FSHD1, OMIM 158900; FSHD2, OMIM 158901)
that share a common pathogenic mechanism linked to epigenetic changes in the chromosome
4q35 D4Z4 macrosatellite array and subtelomeric region [17–19]. This strong epigenetic com-
ponent of FSHDmay account for much of the incomplete penetrance and high clinical vari-
ability in the disease presentation [15–17, 20, 21]. Epigenetic derepression of the 4q35 D4Z4
region leads to the aberrant increased expression of the pathogenic isoform of the DUX4 gene
encoded within the 4q35 D4Z4 array (Fig 1A) [16, 17, 19, 22–24]. Thus, FSHD is essentially a
dominant gain-of-function disease, which makes it amenable to being recapitulated, at least in
part, by transgenic overexpression in model organisms.
The FSHD-associated DUX4 gene encodes at least two different protein isoforms generated
through alternative mRNA splicing (Fig 1B): a non-pathogenic “short” form of unknown func-
tion (DUX4-S) expressed at low levels in healthy somatic cells and a longer “full-length” form
(DUX4-FL) that is expressed in the male germ line and can be highly cytotoxic when expressed
in somatic cells [23, 25–28]. Only expression of the DUX4-FL isoform is linked to FSHD [14,
19, 23]. DUX4-fl encodes a DNA-binding transcription factor with a paired homeodomain,
and DUX4-FL-specific targets include genes expressed in the germ line and in early develop-
ment, immune mediators, and retroelements (Fig 1A) [29, 30]. These DUX4-FL targets are
misregulated in FSHD and, although the mechanisms are still unclear, it is thought that aber-
rant expression of one or more of these targets ultimately lead to accumulated muscle pathol-
ogy [29–31].
Interestingly, two proposed alternative FSHD candidate genes, FRG1 (FSHD region gene 1)
[32] and FRG2 (FSHD region gene 2) [33], localized proximal to the chromosome 4q35 D4Z4
array, were recently identified as direct DUX4-FL target genes [34, 35], thus linking misexpres-
sion of these genes to the widely accepted DUX4 model of FSHD [19]. The molecular function
of FRG2 remains unknown; no FRG2 protein has ever been reported and overexpression of the
FRG2mRNA in mice resulted in no apparent phenotype [36]. By contrast, FRG1 is an impor-
tant for normal development of the vertebrate and invertebrate musculature and vasculature
[36–39]; overexpression of FRG1 leads to a severe myopathy in mice, adversely affects muscle
development and angiogenesis in Xenopus, disrupts muscle structure and organization in C.
elegans, and causes primary defects in myogenic stem cells [27, 36–40]. However, while some
studies reported FRG1 misregulation in FSHD [36, 41, 42], many others failed to find upregu-
lation of FRG1mRNA or protein in FSHD [43–47]. It is possible that FRG1 is only misex-
pressed in the minor subset of DUX4-fl expressing FSHDmyocytes since DUX4-fl expression
can directly influence FRG1 expression, which could account for the difficulty in identifying
changes in expression levels in patient biopsies. Thus, in addition to DUX4-fl, misexpression of
FRG1 may contribute to FSHD pathology and therefore, FRG1 could be a potential therapeutic
target for FSHD.
Fly Expressing FSHDGenes
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Little is known about the cellular pathways affected by DUX4-FL or FRG1 expression dur-
ing early development, myogenesis, or in FSHD. We hypothesized that overexpression models
generated in a genetically tractable system would provide insight into the pathways affected by
DUX4 and FRG1 through the identification of enhancers and suppressors of their functions.
DUX4-FL expression consistently leads to apoptosis in somatic cells and adversely affects fertil-
ity in vertebrate systems [27, 28, 48, 49], and the apoptotic pathway is highly conserved from
invertebrates to human [50, 51]. Thus, although DUX4 is an old world primate-specific gene, a
main pathogenic pathway ultimately activated by DUX4-FL expression is conserved. Similarly,
the mechanism by which increased expression of FRG1 leads to myopathy is not understood.
However, both the sequence and all known biological functions of FRG1 are highly conserved
Fig 1. The DUX4model of FSHD. (A) A model of the human system, which represents a summary of published work relevant to understanding FRG1 and
DUX4 in relation to FSHD supplied to aid the reader with context, showing the FSHD-associated human chromosome 4q35 D4Z4 macrosatellite in healthy
(upper) and FSHD (lower) subjects. In healthy subjects, the D4Z4 array consists of between 11 and ~120 D4Z4 repeat units (RU) and is epigenetically
repressed (black lollipops). FRG1 is ubiquitously expressed, but there is no (or very little) polyadenylated DUX4-fl mRNA expression. In FSHD1 subjects, the
D4Z4 array consists of between 1 and 10 D4Z4 RU, is epigenetically derepressed (yellow lollipops), and a significantly higher fraction of cells than in healthy
subjects express polyadenlylated DUX4-fl mRNA. The DUX4-FL protein, a transcription factor that regulates many genes, can bind to an enhancer located in
intron 2 of FRG1, and expression levels of FRG1 are moderately increased in these DUX4-FL expressing cells [34]. (B) The polyadenylated DUX4-fl mRNA is
derived from the distal repeat of the D4Z4 array. There are two potential translation start sites for DUX4-fl, termed MKG and MAL. Transgenic Drosophila
UAS-DUX4-flMKG andUAS-DUX4-flMAL contain the coding sequence, codon optimized for Drosophila, from the indicated start codon through the stop codon
(red *) in exon 1. Please see the following reviews for relevant references relating to FSHD depicted in this figure [17, 21, 24].
doi:10.1371/journal.pone.0150938.g001
Fly Expressing FSHDGenes
PLOS ONE | DOI:10.1371/journal.pone.0150938 March 4, 2016 3 / 23
between invertebrates and human [52], suggesting that the myopathic mechanism is also con-
served. Drosophila has been used to perform screens for human gene functions by assaying for
overexpression phenotypes and the functions of many human genes are highly conserved [53].
In addition, Drosophila has been used successfully to model neuromuscular diseases, including
six muscular dystrophies, for investigating pathogenic mechanisms and performing genetic
and pharmacologic screens [54–63]. Therefore, we generated Drosophila transgenic lines that
express DUX4-fl or FRG1 under the control of the GAL4-upstream activation sequence (UAS)
[64, 65] to serve as tools to investigate the pathways affected by increased FRG1 or DUX4-FL
expression. Importantly, expression of these genes in Drosophila recapitulated the major phe-
notypes observed in vertebrate systems, apoptosis for DUX4-FL and disrupted musculature for
FRG1. In addition, a set of conditions was identified for both the DUX4-fl and FRG1 lines that
produce readily screenable phenotypes for potential use in future screens for genetic enhancers
and suppressors.
Material and Methods
Drosophila strains
The following fly stocks were obtained from Bloomington Stock Center: DJ667 GAL4 (stock
#8171), Act5C-GAL4 (stock #4414), tubP-GAL4 (stock #5138), longGMR-GAL4 (stock 8605),
nanos-GAL4:VP16 (stock #7312).
Generation of transgenic lines
A DNA fragment encoding the HA epitope tag (YPYDVPDY) preceded by a start codon was
inserted between the EcoRI/BglII sites of the pCaSpeR3 vector [66] to generate pCaSpeR3 HA.
The DmFRG1-coding sequence was amplified by PCR from yw cDNA using DmFRG1 5’
BamHI and DmFRG1 3’ XbaI primers (S3 Table) and then subcloned between the BglII/XbaI
sites of the pCaSpeR3 HA vector to generate HA-DmFRG1- pCaSpeR3. This plasmid was used
to generate UAS-DmFRG1 transgenic lines by standard transformation procedures.
The human DUX4-coding sequence was codon optimized for expression inDrosophila
(http://www.genscript.com/cgi-bin/tools/codon_freq_table), and the entire DUX4-flMKG coding
sequence was synthesized and subcloned into the pUC57 vector, generating HA-DUX4-flMKG
(GenScript USA Inc., S1 Fig). The HA-DUX4-flMKG fragment was subcloned between theNotI/
XbaI sites of the UASp or pUAST vectors. The shorter HA-DUX4-flMAL sequence was PCR-
amplified from HA-DUX4-flMKG-pUC57 and cloned between theNotI/XbaI sites of the UASp
or pUAST vectors. UASp-HA-DUX4-flMKG, pUAST-HA-DUX4-flMKG, UASp-HA-DUX4-fl-
MAL, and pUAST-HA-DUX4-flMAL plasmid DNAs were injected by Duke University Model Sys-
tems Genomics Core in 2010 (this service is no longer available), and G0 larvae (the injectees)
were sent to our laboratory for further crosses to establish and balance the lines.
Production of FRG1 antibodies
Two DmFRG1 rabbit polyclonal antibodies were generated (GenScript Corporation, Piscat-
away, NJ) against synthesized peptides targeting amino acid sequences 228–241 for DM1 and
247–262 for DM2 (NP_649202), and then affinity purified prior to use.
Western Blotting
Total protein was extracted from 100 heads/thoraces or embryos in RIPA extraction buffer
with protease inhibitors and analyzed (50μg total protein per lane) by SDS-PAGE and western
Fly Expressing FSHDGenes
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blotting. Both DM1 and DM2 affinity purified antibodies were used at 1:1500 dilution followed
by 1:5000 Donkey anti-rabbit-HRP antibody (Roche).
qRT-PCR
Adult flies with indicated genotypes were collected at 2 days and 10 days after eclosion and
kept frozen at -80°C. Each frozen fly was dissected into thorax/legs, abdomen, and head on dry
ice, and groups of 40 (20 male and 20 female) were homogenized in TRIzol (Life Technologies)
for total RNA extraction as per manufacturer’s instructions. Total RNAs were treated with
DNase I on column and purified using the RNeasy mini kit according to the manufacturer’s
protocol (QIAGEN). One-step qRT-PCR was performed using 30ng or 15ng of total RNA for
DmFRG1 and rp49 expression analysis, respectively (iTaq Universal SYBR Green One-Step
Kit, Bio-Rad Laboratories). Cycling conditions were: 50°C for 10 min, 95°C for 1 min, then 40
cycles of 95°C for 10 sec, 60°C for 15 sec, and 72°C for 30 sec. The primers used for qPCR anal-
ysis are listed in S3 Table.
Immunofluorescence
Immunofluorescence of ovaries was performed as described with representative images shown
[67]. Eye imaginal discs were dissected from 3rd instar larvae and immunostained as described
with representative images shown [68]. Adult thoraxes were dissected and fixed in 4% parafor-
maldehyde/PBS at 4°C for 1 hour, and then cryoprotected in 12% sucrose/PBS at 4°C overnight
before being embedded in OCT (Tissue Tek). Cryosections (10-μm thick) were immunostained
as described [69]. Antibodies and dilutions used are: rat anti-HA 3F10 (1:200, Roche), mouse
anti-ELAV-9F8A9 (1:10), rabbit anti-DmFRG1 DM1 (1:300), rabbit anti-DmFRG1 DM2
(1:300), and Alexa 594 or 488-conjugated secondary antibodies. Nuclei were visualized with
DAPI (Invitrogen). Elav-9F8A9 was deposited to the Developmental Studies Hybridoma Bank
by G.M. Rubin. For polytene chromosome spreads, salivary glands were dissected from>100
third-instar larvae grown at 25°C and immunofluorescence was performed as described [70].
Histology
Newly hatched flies were placed at 29°C incubator for 10 days before fixation in Carnoy’s solu-
tion at room temperature for overnight. Whole flies (n = 20) were further processed for paraf-
fin sections as described [71]. Paraffin sections (12 μm-thick) were allowed to dry overnight
and stained with hematoxyline and eosin.
Flight assay
Flies were placed at 29°C incubator for 10 days prior to testing. Flight ability was determined
by placing 10-day-old flies in a 20-cm glass vial, allowing the flies to climb the sides, and then
tapping the vial to dislodge them from the sides of the vial. Flies were scored as having
impaired flight ability if they dropped vertically and hit the bottom of the vial instead of flying
to catch the side of the tube.
Repository
Transgenic lines will be available through the Bloomington Drosophila Stock Center at Indiana
University (http://flystocks.bio.indiana.edu/).
Fly Expressing FSHDGenes
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Results
Generation and characterization of UAS-DUX4 transgenic lines
Each D4Z4 repeat unit (RU) from the human chromosome 4q35 array contains an open read-
ing frame encoding the DUX4 transcription factor; however, due to the polyadenylation signal
residing on a third exon located in the subtelomere distal to the D4Z4 array, only the distal
D4Z4 RU produces a stable polyadenylated mRNA and is pathogenic when expressed in myo-
genic cells [19, 23]. The DUX4-FL coding sequence is contained in a single exon with two
potential in-frame methionines that could serve as translation initiation codons: the first at
base pair (bp) 4912 (termed the MKG start codon in reference to the first 3 amino acids) and
the second at bp 5094 (termed the MAL start codon) using the base alignments from the 5’
KpnI site (bp 1) considered the proximal boundary of the first intact D4Z4 of the lamda42
clone [22, 72]. Mapping of capped mRNA transcripts in myogenic cells identified multiple 5’-
capped ends of the DUX4mRNA located from bps 4941–4962, between MKG and MAL, sug-
gesting that MAL is a functional translation initiation codon in vivo, but not precluding that
MKG could be utilized under certain conditions or in other cell types [72]. In fact, the MKG
translation initiation site has recently been reported to generate functional protein in human
mesenchymal stromal cells [73]. Therefore, we synthesized two DNAs, one encoding the
DUX4-FL protein starting fromMKG (DUX4-flMKG) and one encoding DUX4-FL from MAL
(DUX4-flMAL). Both syntheses were codon optimized for expression in Drosophila and con-
tained a single HA epitope tag at the amino terminus (S1 Fig). The two sequences were cloned
into the pUASp [74] and pUAST [64] vectors for germ line and somatic expression, respec-
tively, and each of the four constructs was injected into 125 embryos and analyzed (S1 Table).
Injections of pUAST-DUX4-flMKG and pUAST-DUX4-flMAL transgenes produced very few
transgenic flies, which may not be surprising since even low levels of DUX4-FL are highly cyto-
toxic in vertebrate somatic cells [25, 27, 49], and suggests that this key activity of the human
DUX4-FL protein is conserved in Drosophila. Interestingly, there were differences between the
two transgenes; pUAST-DUX4-flMAL produced 7 independent transgenic lines, all of which
died prior to reproduction, while pUAST-DUX4-flMKG produced 8 transformants, 1 of which
died and 7 of which were sterile. Thus, no stable transgenic lines were generated from either
DUX4-fl sequence using the pUAST somatic expression vector.
UAS-DUX4-fl transgenic lines were successfully generated using the UASp germline expres-
sion vector, with transformants showing 0% mortality. Considering the lethal phenotype gen-
erated with the somatic vector, this was surprising since one might expect low-level leaky
expression in somatic cells even with the germline vector. Likely the transgenes in these cases
inserted into regions of the fly genome that were less favorable to transcription and suppressed
their expression allowing for successful embryogenesis. Again, there were differences found
between the two constructs; offspring from both were fertile, however, the UAS-DUX4-flMKG
transgene produced very weak lines which were ultimately lost, while the UASp-DUX4-flMAL
transformants were relatively healthy and two independent lines, UASp-DUX4 #26 (2nd chro-
mosome insertion) and #55 (3rd chromosome insertion) were successfully established and
used in the following experiments.
In humans, DUX4-fl is expressed in the male germline of healthy individuals, while expres-
sion in the female germline has not been investigated. To determine the effect of DUX4-fl
expression on the Drosophilamale and female germlines, UASp-DUX4 flies were crossed with
nanos (nos) GAL4:VP16, and the testes and ovaries were examined. Neither male nor female
nosGAL4:VP16; UASp-DUX4 showed lethality, however, all male nosGAL4:VP16; UASp-DUX4
flies were sterile and had malformed testis (Fig 2 and Table 1). In contrast, female nosGAL4:
VP16; UASp-DUX4 flies were fertile and had apparently normal ovaries. Immunostaining
Fly Expressing FSHDGenes
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confirmed expression of DUX4-FL during oogenesis. We conclude that DUX4-fl expression
has sex-specific effects on the Drosophila germline with no adverse effects on the ovaries or
female fertility, while the Drosophila testis, as opposed to the case of human males, cannot tol-
erate DUX4-fl expression.
A Drosophilamodel of DUX4-fl for identifying genetic interactions
DUX4-fl is highly cytotoxic when expressed in vertebrate somatic cells in culture or during ver-
tebrate embryonic development [25, 27, 28, 75]. Ubiquitous expression of DUX4-fl during
development induced by tubulin 1@ promoter-GAL4 (tubP-GAL4) [76] or Actin5C promoter-
Fig 2. Effects of DUX4-fl expression on theDrosophila germline. Adult testis and reproductive tract of nosGAL4:VP16/+ (A and A’) and nosGAL4:VP16/
+, UASp-DUX4/+ (B and B’). The nosGAL4:VP16/+ has normally developed testis showing spermatagonia (S) progressing to developing immature sperm
(IS) and accumulated mature sperm (MS). The nosGAL4:VP16, UASp-DUX4male has an extremely small testis with relatively normal accessory gland (AG)
and anterior ejaculatory duct (AD). Magnified picture of nosGAL4:VP16, UASp-DUX4 testis (B’) shows lack of fully matured sperm that are observed in
normal testis (A’, white arrowheads). Adult ovaries of the nosGAL4:VP16/+ (C) and nosGAL4:VP16/+, UASp-DUX4/+ (D). The nosGAL4:VP16/+, UASp-
DUX4/+ ovaries are filled with developing oocytes and are indistinguishable from normal ovaries (C). E and F) Immunostaining of ovariole from nosGAL4:
VP16/+, UASp-DUX4/+ shows HA-DUX4-FL (green) is expressed in mid stage of oogenesis (stage 8); DAPI (blue) and phalloidin (red) staining are shown in
the overlay. Bar = 500 μm in panels A-D, 100 μm in panels A’ and B’, and 50 μm in panel E.
doi:10.1371/journal.pone.0150938.g002
Fly Expressing FSHDGenes
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GAL4 (Act5C-GAL4) resulted in 100% lethality (Table 1) indicating that this developmental
lethal effect is conserved in Drosophila. We attempted to bypass the developmental lethality by
inducing DUX4-fl expression at later stages in the adult muscle by using the DJ667 GAL4 line
reported to express primarily in adult thoracic muscle [77], however, this cross also resulted in
100% lethality (Table 1). Since we were unable to generate viable flies that expressed DUX4-fl
during development or specifically in muscle, we attempted to restrict DUX4 expression to the
Drosophila eye, a commonly used model for developmental processes including cell prolifera-
tion, cell signaling, and apoptosis [51, 78–80] as well as for studying transcription factors [81–
84]. We crossed UAS-DUX4 lines with the long GMR (lGMR)-GAL4 driver line, which
expresses GAL4 in the eye under control of five copies of a 38bp glass-binding site with higher
specificity and less robustness than regular GMR-GAL4 that utilizes a shorter glass-binding
site [78, 85, 86]. Although lGMR-GAL4 induces transgene expression primarily in the photore-
ceptors in the eye imaginal disc during third instar larval stage, F1 offspring showed a predomi-
nant pupal lethal phenotype (Table 1); the cross between lGMR-Gal4/ lGMR-Gal4 and UASp-
Table 1. DUX4 expression phenotypes.
GAL4 Driver Male Female Phenotype
Germline Expression: nosGAL4:VP16/nosGAL4:VP16 x UASp-DUX4/Balancer
nosGAL4:VP16/+; CyO/+ 64 87 NA
nosGAL4:VP16/+; UASp-DUX4 #26/+ 61 74 Male Sterility
nosGAL4:VP16/+; TM3/+ 53 78 NA
nosGAL4:VP16/+; UASp-DUX4 #55/+ 68 86 Male Sterility
Ubiquitous Expression: tubP-GAL4/TM3 x UASp-DUX4/Balancer
CyO/+; tubP-GAL4/+ or UASp-DUX4 #26/+; TM3/+ or CyO/
+; TM3/+
137 149 NA
UAS-DUX4 #26/+; tubP-GAL4/+ 0 0 Lethal
tubP-GAL4/TM3 or UASp-DUX4 55/TM3 129 138 NA
tubP-GAL4 / UASp-DUX4 #55 0 0 Lethal
Ubiquitous Expression: Act5C-GAL4/TM3 x UASp-DUX4/Balancer
CyO/+; Act5C-GAL4/+ or UASp-DUX4 #26/+; TM3/+ or
CyO/+; TM3/+
50 58 NA
UASp-DUX4 #26/+; Act5C-GAL4/+ 0 0 Lethal
Act5C-GAL4/TM3 or UASp-DUX4 #55/TM3 103 110 NA
Act5C-GAL4 / UASp-DUX4 #55 0 0 Lethal
Adult Muscle Expression: DJ667 GAL4/TM3 x UASp-DUX4/Balancer
CyO/+; DJ667 GAL4/+ or UASp-DUX4 #26/+; TM3/+ or
CyO/+; TM3/+
81 74 NA
UASp-DUX4 #26/+; DJ667 GAL4/+ 0 0 Lethal
DJ667 GAL4/TM3 or UASp-DUX4 #55/TM3 88 91 NA
DJ667 GAL4 / UASp-DUX4 #55 0 0 Lethal
Eye Expression: lGMR-GAL4/lGMR-GAL4 x UASp-DUX4/Balancer
lGMR-GAL4/CyO 58 84 NA
lGMR-GAL4 / UASp-DUX4 #26 1 4 Pupal Lethal; Eye
Phenotype
lGMR-GAL4/+; TM3/+ 31 41 NA
lGMR-GAL4/+; UASp-DUX4 #55/+ 0 27 Pupal Lethal; Eye
Phenotype
The numbers of male and female adult ﬂies with the indicated genotype are listed along with any aberrant
phenotype. NA indicates no discernible phenotype.
doi:10.1371/journal.pone.0150938.t001
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DUX4 #26/CyO produced only 5 lGMR-Gal4/ UASp-DUX4 #26 flies while 142 of lGMR-Gal4/
CyO were produced. This is likely due to low ectopic expression of DUX4-fl by lGMR-GAL4 in
other tissues [87]. Lethality was more pronounced in the F1 males, however, a number of F1
females were born (Table 1) that displayed a readily apparent eye phenotype with 100% pene-
trance (Fig 3). Immunostaining confirmed DUX4 protein expression in the eye imaginal discs
of GMR-GAL4, UAS-DUX4 third instar larvae (Fig 4). Importantly, this DUX4-mediated eye
phenotype was distinctly different from those produced by similarly overexpressing other tran-
scription factors in the eye indicating this phenotype was not merely the result of a non-specific
effect due to the overexpression of a transcription factor or signaling protein [80–84]. We con-
clude that we have successfully generated a line of transgenic DUX4-fl Drosophila that can be
Fig 3. EctopicDUX4-fl expression by lGMR-GAL4 produces a readily screenable eye phenotype. A-C) Compound eyes of lGMR-GAL4 consist of
precisely organized and pigmented ommatidia and bristles. D-F) Eyes of lGMR-GAL4/+, UASp-DUX4/+ are the usual size but lack organized ommatidia.
Corneal lenses and pigment cells are completely missing; bristles are formed, but irregularly dispersed. Bar = 100 μm in panel D; Bar = 50 μm in panels E and
F.
doi:10.1371/journal.pone.0150938.g003
Fly Expressing FSHDGenes
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crossed to generate a model that can be utilized for genetic screening to identify potential
genetic enhancers and suppressors of DUX4-FL function.
Generation and characterization of Drosophila transgenic lines of
UAS-DmFRG1
In humans, aberrant upregulation of FRG1 expression, via epigenetic dysregulation of the
FSHD-associated chromosome 4q35 region and, as recently discovered, through the binding of
DUX4-FL, has long been a proposed disease mechanism for FSHD [36, 41, 88]. Overexpression
of FRG1 or its orthologs in mouse, Xenopus, and C. elegans inhibits myogenic cell migration,
leads to defects in myogenic stem cells, disrupts muscle development and function, and recapit-
ulates many features of FSHD [36–40], however the specific pathways leading to these pheno-
types are not known. In contrast to primate-specific DUX4, human FRG1 at chromosome 4q35
is highly conserved in metazoans, including Drosophila, across its entire open reading frame
[32, 52, 89]. Drosophila FRG1 (DmFRG1; CG6480) exhibits 50% amino acid identity (66% simi-
larity) with its human ortholog and contains similar functional domains (Fig 5A); therefore,
we hypothesized that the Drosophila and human FRG1 proteins likely have a conserved biolog-
ical function and Drosophila would be a suitable system for identifying conserved FRG1
affected pathways.
We aimed to use Drosophila to create a genetic tool that could be used to identify and better
understand the cellular pathways disrupted by FRG1 overexpression, and which therefore
might play roles in FSHD pathogenesis. Transgenic Drosophila lines containing the coding
sequence of DmFRG1 with an HA epitope tag at the amino terminus were generated using the
pUAST vector [64]. Since FSHD predominantly affects adult muscles and the human FRG1
gene is a direct transcriptional target of the DUX4-FL protein in FSHD muscle [34], the
UAS-DmFRG1 flies were crossed with the DJ667 GAL4 line, which expresses GAL4
Fig 4. Expression of DUX4-FL in eye imaginal disc leads to disruption of eye formation. Third instar eye imaginal discs from A) lGMR-GAL4/+ or B and
C) lGMR-GAL4/+; UASp-DUX4/+were immunostained for the photoreceptor marker ELAV (green) or HA-DUX4 (red), and stained for DAPI (blue). C)
Expression of DUX4-FL protein was detected in mature photoreceptors posterior to the morphogenetic furrow. Bar = 50 μm and 10 μm in the magnified
picture.
doi:10.1371/journal.pone.0150938.g004
Fly Expressing FSHDGenes
PLOS ONE | DOI:10.1371/journal.pone.0150938 March 4, 2016 10 / 23
Fig 5. FRG1 is highly conserved between human andDrosophila. (A) Alignment of the predicted amino acid sequence for the human (Hs) and D.
melanogaster (Dm) FRG1 orthologs. Conserved amino acids are highlighted in yellow with identical amino acids indicated by the letter and similar amino
acids indicated by a +. The functional domains, including the nuclear localization signals (NLS) and RNA binding domain (RBD), are indicated. The peptides
Fly Expressing FSHDGenes
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predominantly in adult thoracic muscle [77]. Our qRT-PCR analysis confirmed that DJ667
GAL4, DmFRG1 flies showed increased FRG1 expression predominantly in thoracic muscle as
they aged (Fig 5B). With UAS-DmFRG1 line 11, there was a 5-fold overexpression of DmFRG1
mRNA 2 days after hatching that increased to 17-fold at 10 days; with line 12, expression
increased from 32-fold to 50-fold. Both double transgenic lines were viable and fertile.
Tissues from yw and UAS-DmFRG1 adult flies were also assayed for FRG1 protein expres-
sion using two affinity-purified polyclonal antibodies (DM-1 and DM-2) generated against the
carboxyl terminus of DmFRG1 (Fig 5A). These antibodies detect both the endogenous
DmFRG1 protein and the transgenic overexpressed protein (Fig 5C). The transgenic DmFRG1
has an amino terminal HA epitope tag that allows differential detection of endogenous and
overexpressed DmFRG1 (Fig 5C). In vertebrates, FRG1 has multiple distinct subcellular locali-
zations: a nuclear pool associated with nascent mRNA transcripts on the chromatin and nucle-
oli, and a cytoplasmic protein pool [90, 91]. Interestingly, in all model systems we tested
previously, endogenous FRG1 was predominantly, but not exclusively, cytoplasmic and the
overexpression of FRG1 led to preferential accumulation in the nucleus, and particularly in the
nucleolus, suggesting that FRG1 protein levels affect subcellular localization and are likely to be
tightly regulated [90, 91]. Immunostaining for DmFRG1 in Drosophilamuscle and salivary tis-
sues showed a similar pattern (Figs 5D and 6A–6G). As with overexpression in vertebrate cell
culture, all detectable DmFRG1 expressed from the transgene was nuclear in tubP-GAL4,
UAS-DmFRG1 salivary glands (Fig 6, compare panels E and F). In the nuclear pool of
DmFRG1, the overexpressed and endogenous proteins had similar, overlapping subnuclear
localization profiles (Fig 6G). The FRG1 associated with polytene chromosomes preferentially
localized to the DAPI-poor euchromatic puffs (Fig 6L and 6M), and the overexpressed
DmFRG1 showed overlapping localization with the endogenous chromatin-associated
DmFRG1 (Fig 6K). Overall, based on this preliminary examination, DmFRG1 behaves similar
to its vertebrate orthologs.
Overexpression of DmFRG1 in adult muscle disrupts organization of the
musculature and impairs muscle function
FSHD is typically an adult onset progressive myopathy leading to decreased skeletal muscle
mass and ultimately loss of muscle function. FRG1 expression is moderately induced by the
DUX4-FL transcription factor in human myocytes due to a human specific DUX4-FL respon-
sive intronic enhancer [92], and overexpression of FRG1 in muscle results in an FSHD-like
myopathy in mice and impaired muscle development, function, and movement in Xenopus
and C. elegans [36–38, 93]. Therefore, we generated flies overexpressing DmFRG1 in the adult
musculature and assayed them for a basic muscle function: the ability to fly (S1 Movie 1 and 2).
The parent lines DJ667 GAL4 and UAS-DmFRG1, which express wild-type levels of DmFRG1,
are capable of movement and flight indistinguishable from yw flies. However, their progeny
overexpressing DmFRG1 in adult thoracic muscles have substantially impaired flight ability
(Summarized in S2 Table). These DJ667 GAL4, UAS-DmFRG1 flies have fully developed wings,
used as antigens for generating the DM1 and DM2 antibodies are boxed in red. (B) DmFRG1 expression was assayed by qRT-PCR at day 2 (D2) and day 10
(D10) in the thorax or head and abdomen combined, as indicated. Expression was normalized to rp49 RNA levels and presented as fold expression
compared to D2 or D10 thorax. Induction of DmFRG1mRNAwas significant (* p < 0.01 by Student’s t-test) for both lines when compared withw and
DJ667GAL4 alone. (C) Left panel: Western blots of protein extracts from 0–17h embryos (lane 1 and 4) or head/thorax of adult flies (lanes 2, 3, 5, and 6) of yw
strain (lanes 1, 2, 4, and 5) or tubP-GAL4,UAS-DmFRG1 flies (lanes 3 and 6), probed with the DM1 or DM2 antibody as indicated. Beta-tubulin was used as a
loading control. (D) Thoracic muscle tissue immunostained for DmFRG1 (green) and counterstained with DAPI (blue) and phalloidin (red). Endogenous
DmFRG1 is not detectable in the nuclei of yw flies (white arrows) and accumulates in nuclei when overexpressed (yellow arrows). Zoomed regions displayed
in the lower panels are outlined in the upper panels by dotted white boxes.
doi:10.1371/journal.pone.0150938.g005
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are capable of walking normally and jumping for takeoff, but were nonetheless incapable of
sustained flight (S2 Movie). Thus, overexpression of DmFRG1 in flight muscles resulted in
impaired function.
Fig 6. Nuclear localization of endogenous and overexpressed DmFRG1 is conserved. Salivary gland tissue (A-G) and polytene chromosome spreads
(H-M) fromw (A, B) and tubP-GAL4, UAS-DmFRG1 were immunostained for total DmFRG1 using the DM2 antibody (red; A-E, G, I, K, L) or specifically
overexpressed DmFRG1 using the HA antibody (green; F, G, J, K, M), and stained with DAPI (blue) to show the nuclei (A, C) or chromosomes (H, L, M).
Endogenous DmFRG1 is predominantly cytoplasmic (A, B), while overexpressed DmFRG1 accumulates in the nucleus (E, F, G). In the nucleus, the
endogenous and overexpressed DmFRG1 localizations mostly overlap (yellow; G, K).
doi:10.1371/journal.pone.0150938.g006
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Overexpression of FRG1 disrupts the organization and integrity of the musculature in other
model organisms and muscle from FRG1 overexpressing mice show features of muscular dys-
trophy [36–38]. Thus, the thoracic muscles of DmFRG1 overexpressing flies were analyzed his-
tologically and compared with controls for similar indications (Fig 7). Hematoxylin and eosin
(H&E) staining of thoraces revealed that DmFRG1 overexpression leads to a disorganized mus-
culature. The dorsal longitudinal muscles (DLMs) in control flies exhibited the typical pattern
of 12 organized bundles, six on each side (Fig 7A), however, DLMs from the DmFRG1 overex-
pressing flies were misshapen, fused together, and were overall highly disorganized (Fig 7B)
[58]. Analysis of the dorso-ventral muscle bundles suggested muscle degeneration in the ter-
gosternal muscles (indirect with levator muscles) (Fig 7D). Overall, overexpression of
DmFRG1 disrupts the integrity of the musculature and impairs muscle function. We conclude
Fig 7. Abnormal musculature in DM-FRG1 overexpressing flies. H&E stained paraffin sections of
thoraces from DJ667GAL4 (A and C) and of DJ667GAL4; DmFRG1 (B and D) adult flies. (B) Overexpression
of DmFRG1 leads to disorganized dorsal longitudinal muscles (DLMs, indirect wing depressors) exhibiting
variable numbers and shapes of muscles suggestive of muscle degeneration (arrowheads) compared with
the highly organized musculature observed in the controls (A), which exhibit the characteristic 6 distinct
DLMs on each side. (C and D) H&E stained paraffin sections of the dorso-ventral tergosternal muscle
bundles (indirect wing levators) show histological features characteristic of muscle degeneration
(arrowheads). * denotes the samemuscle in these flies for a reference. Bar = 500 μm.
doi:10.1371/journal.pone.0150938.g007
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that we have successfully generated a model of FRG1-mediated muscle dysfunction that is
readily amenable to screening for modifiers of the phenotype.
Discussion
The FSHD pathogenic mechanisms downstream of DUX4-flmisexpression are not well under-
stood due in large part to a lack of phenotypic DUX4-based FSHD-like animal models. Cir-
cumventing DUX4-fl cytotoxicity and lethality during early development has been a major
hurdle inhibiting the generation of viable transgenic FSHD models since even trace amount of
spurious DUX4-fl transcription during embryogenesis can be lethal. In fact, generating the
only viable transgenic mouse line that expresses DUX4-fl mRNA, the D4Z4-2.5 mice, required
more than 450 injections to obtain one viable and fertile line [94], mirroring the situation we
faced while generating the Drosophila DUX4 lines. Compounding the problem, the DUX4 gene
evolved relatively recently and is specific to old-world primates. DUX4 originated from a gene
conversion event in the mammalian DUXCmacrosatellite array that occurred in the primate
and Afrotheria lineages, and subsequently translocated to chromosome 4qter in primates [95,
96]. Therefore, despite apparent homology to ancestral paired homeodomain transcription fac-
tors, which is restricted to the DNA binding domains, traditional model systems such as mice,
rats, flies, and zebrafish do not have true parental DUX4 orthologs and no natural models exist
[95] and one must always consider potential nonspecific effects when working with DUX4
expressed in non-human systems.
Although generally silent in adult somatic tissues, DUX4-fl is expressed normally in human
testis, pluripotent stem cells [23], and many somatic tissues of FSHD1 and healthy fetuses, sug-
gesting that the DUX4 retrogene has likely evolved to function specifically during primate
germ line and embryonic development [97, 98]. Presumably, the DUX4-FL protein co-opted
the host primate genome and cellular machinery to regulate certain endogenous primate genes
and cellular pathways [29–31]. Thus, despite DUX4 being primate-specific, most of the
DUX4-FL target genes and affected pathways are evolutionarily conserved and present in
model organisms, allowing introduction of DUX4-FL to produce a potentially useful model of
certain aspects of FSHD. In fact, Xenopus and zebrafish embryos injected with DUX4-flmRNA
and mice expressing DUX4-fl via viral infection or transgene expression exhibit phenotypes
consistent with FSHD [27, 28, 75, 99]. One caveat is that although many protein-coding
DUX4-FL target genes are conserved, their regulatory elements may not be conserved, resulting
in gene expression patterns that do not fully overlap with FSHD transcription profiles or those
of human cells expressing exogenous DUX4-fl [29, 31, 100]. For example, the human FRG1
gene contains a functional intronic DUX4-FL binding site but this site is absent from the
murine Frg1 gene, rendering it non-inducible by DUX4-FL [92].
A key part of DUX4 evolution in primates includes the silencing of DUX4-fl expression in
adult somatic tissues, where its expression is deleterious. Upon loss of epigenetic silencing in
FSHD, abnormal DUX4-fl expression in adult skeletal muscle has pathological consequences
by aberrantly activating target genes and DUX4-regulated cellular pathways [31]. Low levels of
DUX4-FL are highly cytotoxic when expressed in somatic cells and DUX4-FL expression dis-
rupts vertebrate development [25, 27, 28, 49, 75]. This phenotype is conserved in our Drosoph-
ila DUX4model as evidenced by the difficulty in generating transgenic DUX4 lines and the
observed phenotypes. Although clinical symptoms of FSHDmanifest in adult skeletal muscles,
DUX4-fl expression was lethal at the levels dictated by the muscle or ubiquitous GAL4 drivers,
and we only obtained viable and fertile flies when expression was restricted to the developing
eye. Fortunately this expression pattern still produced a cellular phenotype consistent with
FSHD. However, in addition to the eye phenotype, the developmental lethality induced from
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the ubiquitous Act5c-GAL4 and tubP-GAL4 crosses is another screenable phenotype for DUX4
genetic interactions that may be more relevant in other tissues. Thus, we have generated a via-
ble Drosophilamodel of DUX4 expression that can be utilized to generate flies that are readily
screenable for suppressors or enhancers of the phenotype, the results of which would be of
great interest to the FSHD field.
Two myogenic enhancers proximal to the FSHD-associated 4q35 D4Z4 array were recently
identified and shown to regulate DUX4 in differentiated skeletal myocytes [101], providing a
potential explanation for the relatively muscle-specific pathology seen in FSHD. In addition,
FRG1, a transcriptional target of DUX4-FL in humans, produces a myopathic phenotype gen-
erally consistent with FSHD when overexpressed in muscle [36–38]. We have now generated
transgenic Drosophila lines that, when crossed with an adult muscle-specific GAL4 driver, pro-
duce a model of FRG1-mediated muscle dysfunction that recapitulates many aspects of the
FSHD phenotype. In addition, FRG1 plays a critical role in both myogenesis and angiogenesis.
Crossing to additional GAL4 drivers or performing enhancer/suppressor screens may prove
useful in determining the normal biological functions of FRG1 in these tissues, some of which
may be relevant to FSHD.
Informative Drosophilamodels have been generated for several neuromuscular diseases and
for six of the nine classes of muscular dystrophy including Duchenne [58, 61], myotonic [57,
102], congenital, including certain dystroglycanopathies [58, 59, 103, 104], Emery-Dreyfus [60,
105], oculopharyngeal [56], and limb-girdle [54]; however, no Drosophilamodel for FSHD
based on any candidate gene has been reported. Therefore, the Drosophila lines presented here
that will allow investigations into the functions of two genes important to FSHD and will fill an
important void in FSHD research by providing valuable resources for those studying muscle
development and FSHD.
Conclusions
The primary mediator of FSHD pathophysiology is the aberrant stable expression of the
DUX4-fl mRNA isoform in adult somatic cells. Expression of DUX4-FL in somatic cells can
initiate many potentially adverse downstream events including changes in gene expression, dis-
ruption of RNA and protein metabolism, and the induction of apoptosis. However, little is
known about the precise pathways affected by DUX4-FL expression and it is still not known
which DUX4-mediated changes lead to FSHD pathology. FRG1 has been proposed to be
involved in FSHD, as it is a direct transcriptional target of DUX4-FL, and its overexpression
causes a myopathic phenotype in mice through an unknown mechanism. Thus, there is a need
in the FSHD field for genetically tractable model organisms to investigate the cellular pathways
disrupted by aberrant DUX4-FL and FRG1 expression and to determine which of these path-
ways are potentially involved in pathogenesis. FRG1 is very highly conserved between Dro-
sophila and human and readily amenable to model systems approaches. DUX4, however, is
primate specific and not conserved in Drosophila, and thus is reliant on conservation of the rel-
evant cellular machinery and pathways; successful DUX4-based models have been generated in
Xenopus and Zebrafish despite their lack of DUX4 orthologs. Therefore, we generated trans-
genic lines of Drosophila expressing DUX4-fl or FRG1 under the control of the GAL4-UAS sys-
tem that produced readily screenable phenotypes consistent with what is known about the
functions of these proteins in other systems. Induction of DUX4-fl expression during early
development was lethal and expression in the eye imaginal disc produced resulted in white
ommatidia and disorganized bristles in the adult eye. Induction of FRG1 in the thoracic mus-
cles leads to a disorganized musculature and impaired flight ability. These Drosophila pheno-
types will be valuable tools for performing genetic screens to identify components of the
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DUX4-fl apoptotic pathway and the developmental pathways disrupted by FRG1 expression in
muscle. In addition, Drosophilamodels based on human disease genes, including many muscu-
lar dystrophies, have been used to discover underlying disease mechanisms and for drug
screens to identify potentially therapeutic compounds. The DUX4 and FRG1 transgenic flies
reported here will provide the tools for similar investigations into mechanisms of FSHD.
Supporting Information
S1 Fig. Sequence of the codon optimized DUX4-fl open reading frame. The sequence of the
DUX4-fl cDNA was codon optimized for expression in Drosophila melanogaster and synthe-
sized in vitro. Changed nucleotides are indicated in red.  indicates translational stop codon.
(PDF)
S1 Movie. Increased FRG1 expression in adult muscle impairs flight (Part 1). Groups of
flies were analyzed for the ability to fly. Flies were forcibly dislodged from the surface of a vial
and scored for their ability to prevent themselves from falling to the bottom by flying. Those
that fell were scored as unable to fly; those that immediately lit upon the sides of the vials did
so via flight, thus preventing themselves from falling, and were scored as capable of flying. The
adult muscle GAL4 driver strain DJ667 (left) and the UAS-DmFRG1 strain (right) were readily
able to flying upon being dislodged and return to the sides of the vial. However, the DJ667
GAL4, UAS-DmFRG1 progeny (middle), which produced flies overexpressing DmFRG1 in
their adult muscles, were unable to fly and fell to the bottom of the vial when dislodged.
(MOV)
S2 Movie. Increased FRG1 expression in adult muscle impairs flight (Part 2). A representa-
tive adult DJ667,UAS-DmFRG1 fly, which overexpresses DmFRG1 in its thoracic muscles,
appears normal and is capable of walking and flexing its intact wings but is unable to fly. These
flies jump into the air for take-off as per usual, however, instead of flying they fall back down
immediately.
(MOV)
S1 Table. UAS-DUX4 transgenesis results.
(PDF)
S2 Table. Overexpression of DmFRG1 in adult thorax impairs flight ability.
(PDF)
S3 Table. Oligonucleotides used for cloning and qPCR.
(PDF)
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